Michael Charlton

Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age

Mary E. Rinella, Michael Charlton, Yestle Kim, Suneil Hosmane et autres

us (code pays fourni par la source)

Response to “Aspirin for Primary Prevention in Metabolic Dysfunction‐Associated Steatotic Liver Disease”

Tsubasa Tsutsumi, Michael Charlton, Takumi Kawaguchi, Mary E. Rinella

jp, us (code pays fourni par la source)

Two-year time course of biomarker and imaging responses in well-compensated MASH cirrhosis patients treated with resmetirom

J M Schattenberg, Rebecca Taub, Naim Alkhouri, Xiaomin Lu et autres

us, de (code pays fourni par la source)

Assessing Predictive Performance of Fibrosis-4 Index in Settings With Lower Prevalence of Liver Fibrosis

Mary E. Rinella, Michael Charlton, Yestle Kim, Suneil Hosmane et autres

us (code pays fourni par la source)

EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH

Daniel Kim, Yestle Kim, Michael Charlton, John J. O’Donnell et autres

us (code pays fourni par la source)

Aspirin Use and Mediterranean Diet Adherence as Factors Associated With Overall Mortality in Patients With MASLD in NHANES

Tsubasa Tsutsumi, Michael Charlton, Vanessa M. Oddo, Sarah Vilt et autres

jp, us, kr (code pays fourni par la source)

Efficacy and safety of ervogastat alone and in combination with clesacostat in patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and F2–F3 fibrosis (MIRNA): results from a phase 2, randomised, double-blind, double-dummy study

Vincent Wai‐Sun Wong, Neeta B. Amin, Hirokazu Takahashi, Amanda Darekar et autres

hk, us, jp, gb, de (code pays fourni par la source)

Awareness of metabolic dysfunction–associated steatotic liver disease (MASLD) in 4 major cities in the United States

Jeffrey V. Lazarus, Trenton M. White, Alina M. Allen, Silvana Pannain et autres

us, es (code pays fourni par la source)

THU-030 Risk factor awareness for liver disease in four United States cities

Trenton M. White, Scott Isaacs, Norah A. Terrault, Mary E. Rinella et autres

TOP-506 Outcomes for patients listed for liver transplantation with low MELD-Na scores: high frequency of MELD-Na score increases, liver transplantation, death and removal from waitlist

Mary E. Rinella, Alan L. Hutchison, Thomas G. Cotter, Michael Charlton et autres

LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis

Naim Alkhouri, Rebecca Taub, Xiaomin Lu, Richard Pushkin et autres

SAT-424 Baseline characteristics in well-compensated NASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome phase 3 study assessing the effect of resmetirom in well compensated NASH cirrhosis

Jörn M. Schattenberg, Meena B. Bansal, Rebecca Taub, Dominic Labriola et autres